by David Kent | May 28, 2013
. A few weeks ago, Italian private company Stamina came under considerable pressure regarding their controversial use of mesenchymal stem cells in patients. The Italian government, it seems, had authorized an unproven stem cell therapy for use in patients. The...
by David Brindley | Apr 22, 2013
. Within the past few weeks, we have all lost someone who has impacted our lives. And this I can guarantee. On Monday 8th April 2013, I woke up, grabbed my tennis bag and headed for a morning hit. In the car, I heard the lacquered voice of the BBC’s John Humphrys...
by David Brindley | Mar 19, 2013
. Part 5 in Cell Therapy Industry 2027 series A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the...
by Natasha Davie | Mar 5, 2013
When it comes to the cell therapy commercialization crunch there are some fundamental questions that need to be answered. Is your product going to be frozen or fresh? How will the product be administered? What is your dosing strategy? And the one that I’m going to...
by David Brindley | Jan 16, 2013
claimtoken-510012802486f [pullquote]The cell therapy industry has an encyclopaedic void. But is this void one that needs addressing?”[/pullquote]This post was initially intended to be a short vignette (not so short, as it turns out) exploring whether or not the...
Comments